Clinical trial
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer (MINIMAX): a Dutch Multicenter Observational Study to Gain Insight in Less and More Invasive Axillary Staging and Treatment in Relation to Oncologic Safety and Quality of Life to Develop Evidence-based Guidelines.
NCT04486495 is registered in ClinicalTrials.gov with Maastricht University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer (MINIMAX): a Dutch Multicenter Observational Study to Gain Insight in Less and More Invasive Axillary Staging and Treatment in Relation to Oncologic Safety and Quality of Life to Develop Evidence-based Guidelines.
- Lead sponsor
- Maastricht University Medical Center
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- July 16, 2020
- Completion date
- July 1, 2027
- Enrollment
- 549 (estimated)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, lymph node metastases, neoadjuvant therapy